title: Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure.
abstract: The present study was conducted to determine whether malnutrition in patients with chronic renal failure requiring cyclosporine therapy for renal transplantation has some effect on the clinical pharmacokinetics of cyclosporine. Eleven pediatric patients were enrolled in this study before renal transplantation and divided into two groups (group I: six well-nourished patients with a deficit in weight/height ratio < or = 7%; group II: five malnourished patients with a deficit in weight/height > 8%). The patients received a single oral dose of cyclosporine (3.0 mg/kg). Blood samples were collected for a 26-hour period, and serum concentrations of cyclosporine were measured using fluorescence-polarization immunoassay technology. The results suggest that, when malnutrition is present, the median Cmax of cyclosporine decreases by almost threefold (from 387.5 ng/mL in group I to 136.1 ng/mL in group II). An observed 52% reduction in AUC0-infinity (from 2,856.0 ng/mL/hr in group I to 1,481.4 ng/mL/hr in group II) was caused by the increased volume of distribution (from 4.6 L/kg in group I to 11.1 L/kg in group II). The elimination half-life (t1/2) was longer in group II compared with that of group I (12.4 hr for group II; range, 7.8-13.5 hr versus 8.9 hr for group I; range, 5.2-16.0 hr). Differences in t1/2 were not statistically significant at 5% confidence intervals. The effects of energy malnutrition on the pharmacokinetics of cyclosporine could explain in part some of the interindividual variability. This study provides pharmacokinetic guidelines for the use of cyclosporine.
authors.affiliation: Division of Experimental Medicine, Instituto Nacional de Pediatría, México City, México.
authors.forename: I
authors.initials: I
authors.lastname: Lares-Asseff
authors.forename: S
authors.initials: S
authors.lastname: Zaltzman
authors.forename: M G
authors.initials: MG
authors.lastname: Pérez Guillé
authors.forename: G A
authors.initials: GA
authors.lastname: Camacho
authors.forename: T
authors.initials: T
authors.lastname: Murguía
authors.forename: M C
authors.initials: MC
authors.lastname: López
authors.forename: A R
authors.initials: AR
authors.lastname: Toledo
authors.forename: A B
authors.initials: AB
authors.lastname: Zaltzman-Rudy
authors.forename: J
authors.initials: J
authors.lastname: Cravioto
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D015362:Child Nutrition Disorders / Q000150:complications / Q000503:physiopathology*; D016572:Cyclosporine / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics*; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000503:physiopathology*; D016030:Kidney Transplantation; D008297:Male; D011502:Protein-Energy Malnutrition / Q000150:complications / Q000503:physiopathology*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine